Old Web
English
Sign In
Acemap
>
authorDetail
>
Denes Csonka
Denes Csonka
Novartis
Buparlisib
Medicine
Immunology
Abiraterone acetate
Prostate cancer
5
Papers
254
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer
2017
European Journal of Cancer
Christophe Massard
Kim N. Chi
Daniel Castellano
Johann S. de Bono
Gwenaelle Gravis
Luc Dirix
Jean-Pascal Machiels
Alain C. Mita
Begoña Mellado
Sabine Turri
Joan Maier
Denes Csonka
Arunava Chakravartty
Karim Fizazi
Show All
Source
Cite
Save
Citations (41)
Corrigendum to ‘Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer’ [European Journal of Cancer 76 (2017) 36–44]
2017
European Journal of Cancer
Christophe Massard
Kim N. Chi
Daniel Castellano
Johann S. de Bono
Gwenaelle Gravis
Luc Dirix
Jean-Pascal Machiels
Alain C. Mita
Begoña Mellado
Sabine Turri
Joan Maier
Denes Csonka
Arunava Chakravartty
Karim Fizazi
Show All
Source
Cite
Save
Citations (2)
A phase‐1, open‐label, single‐dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment
2016
The Journal of Clinical Pharmacology
Denes Csonka
Katharine Hazell
Edward Waldron
Sebastien Lorenzo
Vincent Duval
Lucia Trandafir
Zhanna Kobalava
Show All
Source
Cite
Save
Citations (4)
2550 Phase Ib study of abiraterone acetate (AA) plus buparlisib (BKM120) or BEZ235 in patients (pts) with castration-resistant prostate cancer (CRPC)
2015
European Journal of Cancer
Kim N. Chi
Daniel Castellano
J. de Bono
Gwenaelle Gravis
Luc Dirix
J-P Machiels
Alain C. Mita
B. Mellado Gonzalez
Christophe Massard
L. Trandafir
D. Dey .
Denes Csonka
Arunava Chakravartty
Karim Fizazi
Show All
Source
Cite
Save
Citations (2)
A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
2015
Clinical Cancer Research
Philippe L. Bedard
Josep Tabernero
Filip Janku
Zev A. Wainberg
Luis Paz-Ares
Johan Vansteenkiste
Eric Van Cutsem
Jose Perez-Garcia
Anastasios Stathis
Carolyn D. Britten
Ngocdiep T. Le
Kirsten Carter
David Demanse
Denes Csonka
Malte Peters
Angela Zubel
Heidi Nauwelaerts
Cristiana Sessa
Show All
Source
Cite
Save
Citations (205)
1